FW In Conversation: Mineralys CEO Jon Congleton on Reviving Hypertension Innovation and Lorundrostat’s Best-in-Class Potential
Mineralys CEO Jon Congleton featured in 'FW In Conversation' published January 16, 2026, discussing innovation revival in hypertension and positioning lorundrostat as a potential best-in-class aldosterone synthase inhibitor.8
Lorundrostat targets unmet needs in uncontrolled and resistant hypertension, affecting ~20 million US patients, with only 20% achieving blood pressure goals.1
Recent Phase 3 Launch-HTN trial recognized by JAMA as 'Research of the Year' for significant blood pressure reductions in difficult-to-treat patients.45
Company plans NDA filing by end of 2025 or Q1 2026, with Explore-OSA data expected Q1 2026 to support expansion into comorbid conditions.17
Lorundrostat shows 15-19 mmHg blood pressure reductions, strong physician intent to prescribe (95%), and safety profile similar to RAS inhibitors.16
Sources:
1. https://www.investing.com/news/transcripts/mineralys-at-guggenheim-conference-promising-hypertension-treatment-93CH-4349499
4. https://ir.mineralystx.com/news-events/press-releases/detail/88/mineralys-therapeutics-phase-3-launch-htn-trial-of
5. https://www.globenewswire.com/news-release/2025/12/12/3204783/0/en/Mineralys-Therapeutics-Phase-3-Launch-HTN-Trial-of-Lorundrostat-Recognized-in-Inaugural-Journal-of-the-American-Medical-Association-JAMA-Research-of-the-Year-Roundup.html
6. https://ir.mineralystx.com/news-events/press-releases/detail/80/mineralys-therapeutics-presents-subgroup-analyses-of-phase
7. https://ir.mineralystx.com/news-events/press-releases/detail/89/mineralys-therapeutics-provides-corporate-update-and